The addition of Swiss drug major Roche's MabThera (rituximab) to chemotherapy in previously untreated patients with chronic lymphocytic leukaemia (CLL) significantly improves chances of survival, according to data presented today at the AmericanSociety of Hematology annual meeting in New Orleans. This is the first time that any treatment for CLL, the most common leukemia in the UK, has been shown to extend life in a randomized clinical trial.
Sales of MabThera, used to treat non-Hodgkin's lymphoma and rheumatoid arthritis, increased 2.7% to 1.51 billion Swiss francs ($1.49 billion) in the third quarter of 2009, lagging analyst estimates of 1.61 billion francs. However, Roche's taking full control of its part-owned US subsidiary Genentech, which developed the drug, will boost income from this best-selling cancer therapy, also known as Rituxan.
The same trial presented at the meeting showed that the addition of rituximab to chemotherapy doubles the number of patients achieving complete remission and lengthens the period of time before the disease returns by more than 1.5 years, compared to chemotherapy alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze